Pharming has since started exploring new uses for the drug in acute kidney injury and COVID-19 pneumonia, whilst working on a gene therapy approach for HAE with Orchard Therapeutics.

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST ...

Chief Executive Officer, Sijmen de Vries, commented: “Pharming has delivered another strong quarter of revenue growth, increasing quarterly revenues by 35% to US$74.1 million. We are firmly on ...

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor ...

To participate in the conference call, please register in advance using the link below. Once registered, dial-in in Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext ...

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States ...

A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. H.C. Wainwright 26th Annual Global Investment ...

Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...